Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Lopes, V. Martins, W. Teodoro, E. R. Parra, V. L. Capelozzi (São Paulo, Brazil). Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene. Eur Respir J 2013; 42: Suppl. 57, 4895

Member's Comments

No comment yet.

Related content which might interest you: Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Collagen V overexpression correlates with IL-17+ cells in C57BL/6 mice pulmonary remodeling Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Metalloproteases gene expression and remodeling of lung parenchyma fibers during the progression of elastase induced emphysema Source: International Congress 2014 – Mechanisms of COPD and inhalation injury Year: 2014 Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 KCa3.1 channel inhibition prevents fibrotic responses in a human lung explant model Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Adventitial remodeling of experimental pulmonary hypertension induces myofibroblast-produced collagen V in a Th17-pathways-related manner Source: International Congress 2016 – Pulmonary hypertension: novel insights Year: 2016 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Resveratrol regulates ECM remodeling in lung fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Thymosin beta4 protects mice from bleomycin-induced damage in the lung Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Regulation of autophagy in amiodarone induced pulmonary fibrosis Source: Annual Congress 2013 –The vulnerable patient and ageing cells Year: 2013 Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 FGF-9 overexpression prevents pleural fibrosis induced by intra-pleural adenovirus injection in mice Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Silica-induced inflammasome activation in vitro and in rat lungs Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013